Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 59 for “"tocilizumab"”.
-
Assessing The Comparative Effect Of Tocilizumab On Risk Of Cardiovascular Disease Among Rheumatoid Arthritis Patients Using Claims Data: A Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs
ASSESSING THE COMPARATIVE EFFECT OF TOCILIZUMAB ON RISK OF CARDIOVASCULAR DISEASE AMONG RHEUMATOID ARTHRITIS PATIENTS USING CLAIMS DATA: A DIRECT COMPARISON AMONG BIOLOGIC DISEASEMODIFYING ANTIRHEUMATIC DRUGS FENGLONG XIE PhD-EPID ABSTRACT Tocilizumab is a humanized monoclonal anti-body against the …
-
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
OBJECTIVES: Tocilizumab showed trends for improving skin fibrosis and prevented progression of lung fibrosis in systemic sclerosis (SSc) in randomised controlled clinical trials. We aimed to assess safety and effectiveness of tocilizumab in a real-life setting using the European Scleroderma Trial …
-
Ischemic Stroke Damage Is Reduced By Inhibition of Il-6 Signaling With to cilizumab
… {3}. Preliminary work in our lab has shown that tocilizumab, an FDA approved immunosuppressive drug that blocks IL-6 receptors to inhibit the pro-inflammatory effects of IL-6, reduced infarct size in young male mice following ischemic stroke. Based on this promising preliminary data, we now …
-
Έκβαση βαρέως πασχόντων COVID-19 ασθενών που λαμβάνουν υψηλή και χαμηλή δόση δεξαμεθαζόνης σε συνδυασμό με anti-IL6 μονοκλωνικό αντίσωμα (Tocilizumab) στη Μονάδα Εντατικής Θεραπείας
… υψηλότερης δόσης κορτικοστεροειδών ή/και Tocilizumab είναι υπό διερεύνηση. Σκοπός: Να αξιολογηθούν οι διαφορές ως προς την έκβαση και τις επιπλοκές των διαφορετικών δόσεων κορτικοστεροειδών (υψηλή δόση vs συνήθους δόσης) συν/πλην Tocilizumab. Υλικό και Μέθοδος: Πραγματοποιήθηκε μία …
-
Μελέτη της θεραπευτικής δράσης της τοσιλιζουμάμπης σε πειραματικό μοντέλο αρθρίτιδας νεαρών επίμυων και η δράση αυτής στην οστική πυκνότητα και τις τενόντιες δομές
… present study was to investigate the effect of tocilizumab, an antibody that binds the Interleukin-6 (IL-6) Receptor, on inflammation-related bone loss and tendon inflammation in an animal model of JIA. In the present study, 155, male, 6-8-week-old, Wistar rats were used. The Collagen-Induced …
-
THE ROLE OF THE TUMOR MICROENVIRONMENT IN WALDENSTRÖM MACROGLOBULINEMIA
… growth and IgM secretion by malignant B cells. Tocilizumab/Actemra is an anti-IL-6R antibody, which can competitively block IL-6 binding to the IL-6R. In this dissertation, we investigated the efficacy of targeting the TME using Tocilizumab in a preclinical mouse model of WM that considers the …
-
Antagonizing autocrine Interleukin-6 receptor signaling inhibits prostate cancer growth in bone
… blocked autocrine IL-6 receptor signaling using tocilizumab and bone resorption using zoledronic acid for a period of 30 days. Tumors were analyzed by histomorphometry, immunohistochemistry for Ki-67 and RANK expression as well as by TUNEL staining. Osteolytic lesions were measured by X-ray …
-
The influence of Interleukin-6 Receptor antibodies on breast cancer metastases in bone
… cancer cells with the anti-human IL-6R mAb tocilizumab or inhibition of IL-6 signalling in cells of the bone microenvironment with the anti-murine IL-6R mAb MR16-1 affects tumour progression and tumour-induced osteolysis in a mouse model of breast cancer bone metastases. Athymic nude mice …
-
MECHANISTIC COUPLING OF CANCER CELL PROLIFERATION AND MIGRATION
… inhibition of IL-6 and IL-8 receptors using Tocilizumab and Reparixin significantly decreases the expression of Arpc2, an important subunit of the Arp2/3 complex, in a mouse xenograft model and consequently reduces metastasis While therapeutic intervention with Tocilizumab and Reparixin …
-
Die Sicherheit der Therapie mit Biologika bei rheumatoider Arthritis
… (PJ) lag die rohe IR bei Patienten unter Tocilizumab-Therapie höher als unter allen anderen Therapien (0,2-0,6/1.000 PJ). Als Risiko-faktoren für Perforation des unteren Darmtraktes stellten sich höheres Alter sowie die Therapie mit Glukokortikoiden, nicht-steroidalen Antirheumatika und …
-
Understanding the role of inflammation in depression and cognitive functioning
… randomised controlled trial of <br/>tocilizumab (anti-IL-6 receptor monoclonal antibody) vs placebo in patients with depression <br/>and evidence of inflammation. I found evidence indicating IL-6 inhibition with tocilizumab <br/>possibly improves certain clinical and cognitive …
-
Extended analysis of the randomised comparisons of the RECOVERY trial immunomodulatory COVID-19 treatments
… treatments are dexamethasone (a corticosteroid), tocilizumab (an interleukin-6 receptor antagonist), and baricitinib (a Janus kinase inhibitor).</p> <p><strong>Methods:</strong> An extended analysis was performed of additional efficacy, safety, and exploratory assessments, including: long-term …
-
Preclinical and Clinical Targeting of Inflammatory Mediators in Triple Negative Breast Cancer
… mouse models, we investigated the efficacy of tocilizumab, anti-IL-6R antagonist. Tocilizumab combined with chemotherapy provided significant tumor growth reduction compared to chemotherapy alone in mice with MAPK active TNBC xenografts. Conversely, the combinational regimen provided no benefit …
-
The role of Interleukin-6 in the metabolism of the ApoB-containing lipoproteins in rheumatoid arthritis
… of interleukin-6 (IL-6) signalling with the drug tocilizumab conveys perhaps the most profound lipid changes, leading to average increases in LDL-cholesterol (LDL-c) of around 20% as well as changes in HDL-cholesterol (HDL-c) and triglycerides. The mechanisms behind this so-called “lipid paradox”, …
-
Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric carcinomas
… GC cells. When monoclonal anti-IL-6R antibody (tocilizumab) was added to chemotherapeutic agents, CAF-induced inhibition of apoptosis was notably abrogated in GC cells. Furthermore, tocilizumab had the same synergistic effects during chemotherapy on GC xenograft tumors in animal models. Clinical …
-
Developing A Physiologically Relevant Model of Pancreatic Cancer
… IL-6 and IL-8 via two FDA approved inhibitors, Tocilizumab and Reparixin, reduced the migratory phenotype of metastatic MDA-MB-231 and HT1080 cell lines in-vitro. This combination therapy tested in-vivo showed reduced metastatic burden could be achieved. This study explores the effect of …
-
The role of human bone marrow mesenchymal stromal cells in pancreatic cancer growth
… trans-signaling by anti-IL-6 receptor antibody Tocilizumab or IL-6 trans-signaling by transfusion protein sgp130Fc in a heterotopic nude mouse model of human BxPc3 xenografts abrogated MSC mediated tumor-promoting effects delaying tumor formation significantly. In addition, Tocilizumab inhibited …
-
The use of biologicals in the treatment of inflammatory diseases: a single center experience in a large Swiss university hospital
… required. Biological agents such as rituximab, tocilizumab or anti TNF antibodies showed promising results. Hence, we investigated the impact of biologicals on the prescription of GCs, clinical improvement and laboratory findings. Method: We performed a retrospective analysis of the medical …
Page 1 of 3